Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Notified -
Globe Newswire30-05-2025, 17:00
Pangea Releases Annual Report + Advanced Products 11-12-2023, 22:00